Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study.
Axial spondyloarthritis
Disease activity trajectories
Drug survival
Etanercept
Psoriatic arthritis
Rheumatoid arthritis
Tumor necrosis factor inhibitor
Journal
Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885
Informations de publication
Date de publication:
10 Oct 2023
10 Oct 2023
Historique:
received:
27
06
2023
accepted:
01
09
2023
medline:
10
10
2023
pubmed:
10
10
2023
entrez:
10
10
2023
Statut:
aheadofprint
Résumé
To characterize disease activity trajectories and compare long-term drug retention between rheumatoid (RA) and spondylarthritis (SpA) patients initiating tumor necrosis factor inhibitor (TNFi) treatment (etanercept). Prospective observational study of RA, axial (AxSpA) and peripheral SpA (PerSpA) patients initiating etanercept during 2004-2020. Kaplan-Meier plots were used for drug retention comparisons and multivariable Cox regression models for predictors of discontinuation. Long-term disease activity trajectories were identified by latent class growth models using DAS28-ESR or ASDAS-CRP as outcome for RA and AxSpA respectively. We assessed 711 patients (450 RA, 178 AxSpA and 83 PerSpA) with a median (IQR) follow-up of 12 (5-32) months. At 5 years, 22%, 30% and 21% of RA, AxSpA and PerSpA patients, respectively, remained on therapy. Etanercept discontinuation was independent of the diagnosis and was predicted by gender and obesity in both RA and SpA groups. Four disease activity (DA) trajectories were identified from 6th month of treatment in both RA and AxSpA. RA patients in remission-low DA groups (33.7%) were younger, had shorter disease duration, fewer comorbidities and lower baseline disease activity compared to moderate (40.6%) & high DA (25.7%) groups. In AxSpA 74% were in inactive-low DA and they were more often males, non-obese and had lower number of comorbidities compared to higher ASDAS-CRP trajectories. In RA and AxSpA patients, disease activity trajectories revealed heterogeneity of TNFi treatment responses and prognosis. Male gender, lower baseline disease activity and fewer comorbidities, characterize a favourable outcome in terms of disease burden accrual and TNFi survival.
Identifiants
pubmed: 37815625
doi: 10.1007/s00296-023-05455-7
pii: 10.1007/s00296-023-05455-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Pfizer Pharmaceuticals
ID : 55999165
Informations de copyright
© 2023. The Author(s).
Références
Navarro-Compán V, Sepriano A, El-Zorkany B, van der Heijde D (2021) Axial spondyloarthritis. Ann Rheum Dis 80:1511–1521. https://doi.org/10.1136/annrheumdis-2021-221035
doi: 10.1136/annrheumdis-2021-221035
pubmed: 34615639
Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388:2023–2038. https://doi.org/10.1016/s0140-6736(16)30173-8
doi: 10.1016/s0140-6736(16)30173-8
pubmed: 27156434
RA-MAP Consortium (2018) Novel methodology to discern predictors of remission and patterns of disease activity over time using rheumatoid arthritis clinical trials data. RMD Open 4:e000721. https://doi.org/10.1136/rmdopen-2018-000721
doi: 10.1136/rmdopen-2018-000721
pmcid: 6241979
Bykerk VP, Lee EB, Van Vollenhoven R, Gruben DC, Fallon L, Woolcott JC et al (2022) Identification of distinct disease activity trajectories in methotrexate-naive patients with rheumatoid arthritis receiving Tofacitinib over twenty-four months. Arthritis Care Res 74:131–141. https://doi.org/10.1002/acr.24709
doi: 10.1002/acr.24709
Pournara E, Kormaksson M, Nash P, Ritchlin CT, Kirkham BW, Ligozio G et al (2021) Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis. RMD Open 7:e001845. https://doi.org/10.1136/rmdopen-2021-001845
doi: 10.1136/rmdopen-2021-001845
pubmed: 34795065
pmcid: 8603280
Taylor PC, Chen Y-F, Pope J, Weinblatt M, Mysler E, Rubbert-Roth A et al (2023) Patient disease trajectories in rheumatoid arthritis patients treated with baricitinib 4-mg in four phase 3 clinical studies. Rheumatol Ther 10:463–476. https://doi.org/10.1007/s40744-022-00529-7
doi: 10.1007/s40744-022-00529-7
pubmed: 36662442
pmcid: 10011235
Hamann PDH, Pauling JD, McHugh N, Hyrich K, Shaddick G, and the BSRBR-RA Contributors Group (2020) Early response to anti-TNF predicts long-term outcomes including sustained remission: an analysis of the BSRBR-RA. Rheumatology 59:1709–1714. https://doi.org/10.1093/rheumatology/kez518
doi: 10.1093/rheumatology/kez518
pubmed: 31714580
Koo BS, Eun S, Shin K, Hong S, Kim Y-G, Lee C-K et al (2022) Differences in trajectory of disease activity according to biologic and targeted synthetic disease-modifying anti-rheumatic drug treatment in patients with rheumatoid arthritis. Arthritis Res Ther 24:233. https://doi.org/10.1186/s13075-022-02918-3
doi: 10.1186/s13075-022-02918-3
pubmed: 36242075
pmcid: 9563490
Movahedi M, Cesta A, Li X, Bombardier C, OBRI investigators. (2022) Disease activity trajectories for early and established rheumatoid arthritis: Real-world data from a rheumatoid arthritis cohort. PLoS ONE 17:e0274264. https://doi.org/10.1371/journal.pone.0274264
doi: 10.1371/journal.pone.0274264
pubmed: 36070307
pmcid: 9451079
Courvoisier DS, Alpizar-Rodriguez D, Gottenberg JE, Hernandez MV, Iannone F, Lie E et al (2016) Rheumatoid arthritis patients after initiation of a new biologic agent: trajectories of disease activity in a Large Multinational Cohort Study. EBioMedicine 11:302–306. https://doi.org/10.1016/j.ebiom.2016.08.024
doi: 10.1016/j.ebiom.2016.08.024
pubmed: 27558858
pmcid: 5049989
Dagliati A, Plant D, Nair N, Jani M, Amico B, Peek N et al (2020) Latent class trajectory modeling of 2-component disease activity score in 28 joints identifies multiple rheumatoid arthritis phenotypes of response to biologic disease-modifying antirheumatic drugs. Arthritis Rheumatol 72:1632–1642. https://doi.org/10.1002/art.41379
doi: 10.1002/art.41379
pubmed: 32475078
Gwinnutt JM, Norton S, Hyrich KL, Lunt M, Combe B, Rincheval N et al (2022) Exploring the disparity between inflammation and disability in the 10-year outcomes of people with rheumatoid arthritis. Rheumatology 61:4687–4701. https://doi.org/10.1093/rheumatology/keac137
doi: 10.1093/rheumatology/keac137
pubmed: 35274696
pmcid: 9707289
Molto A, Tezenas du Montcel S, Wendling D, Dougados M, Vanier A, Gossec L (2017) Disease activity trajectories in early axial spondyloarthritis: results from the DESIR cohort. Ann Rheum Dis 76:1036–1041. https://doi.org/10.1136/annrheumdis-2016-209785
doi: 10.1136/annrheumdis-2016-209785
pubmed: 27888172
De Craemer A-S, Renson T, Deroo L, Van Praet L, Cypers H, Varkas G et al (2022) Peripheral manifestations are major determinants of disease phenotype and outcome in new onset spondyloarthritis. Rheumatology (Oxford) 61:3279–3288. https://doi.org/10.1093/rheumatology/keab887
doi: 10.1093/rheumatology/keab887
pubmed: 34850859
Imkamp M, Lima Passos V, Boonen A, Arends S, Dougados M, Landewé R et al (2018) Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life. RMD Open 4:e000755. https://doi.org/10.1136/rmdopen-2018-000755
doi: 10.1136/rmdopen-2018-000755
pubmed: 30487997
pmcid: 6241970
Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT et al (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62:22–32. https://doi.org/10.1002/art.27227
doi: 10.1002/art.27227
pubmed: 20039405
Flouri ID, Markatseli TE, Boki KA, Papadopoulos I, Skopouli FN, Voulgari PV et al (2018) Comparative analysis and predictors of 10-year tumor necrosis factor inhibitors drug survival in patients with spondyloarthritis: first-year response predicts longterm drug persistence. J Rheumatol 45:785–794. https://doi.org/10.3899/jrheum.170477
doi: 10.3899/jrheum.170477
pubmed: 29606666
Guillot X, Prati C, Sondag M, Wendling D (2017) Etanercept for treating axial spondyloarthritis. Expert Opin Biol Ther 17:1173–1181. https://doi.org/10.1080/14712598.2017.1347156
doi: 10.1080/14712598.2017.1347156
pubmed: 28682112
Lethaby A, Lopez-Olivo MA, Maxwell L, Burls A, Tugwell P, Wells GA (2013) Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD004525.pub2
doi: 10.1002/14651858.CD004525.pub2
pubmed: 24323914
pmcid: 10247921
Bertsias A, Avgoustidis N, Papalopoulos I, Repa A, Kougkas N, Kalogiannaki E et al (2022) Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study. Arthritis Res Ther 24:132. https://doi.org/10.1186/s13075-022-02826-6
doi: 10.1186/s13075-022-02826-6
pubmed: 35655317
pmcid: 9161491
Prevoo MLL, Van’T Hof MA, Kuper HH, Van Leeuwen MA, Van De Putte LBA, Van Riel PLCM (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48
doi: 10.1002/art.1780380107
pubmed: 7818570
Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G et al (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 42:244–257
doi: 10.1093/rheumatology/keg072
pubmed: 12595618
Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K et al (2005) Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 7:R796-806. https://doi.org/10.1186/ar1740
doi: 10.1186/ar1740
pubmed: 15987481
pmcid: 1175030
Pincus T, Summey JA, Soraci SA, Wallston KA, Hummon NP (1983) Assessment of patient satisfaction in activities of daily living using a modified stanford health assessment questionnaire. Arthritis Rheum 26:1346–1353. https://doi.org/10.1002/art.1780261107
doi: 10.1002/art.1780261107
pubmed: 6639693
Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol 21:2286–2291
pubmed: 7699630
Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J et al (2009) Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 68:18–24. https://doi.org/10.1136/ard.2008.094870
doi: 10.1136/ard.2008.094870
pubmed: 18625618
Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K et al (2012) Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 64:640–647. https://doi.org/10.1002/acr.21649
doi: 10.1002/acr.21649
pubmed: 22473918
Machado P, Landewe R, Lie E, Kvien TK, Braun J, Baker D et al (2011) Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70:47–53. https://doi.org/10.1136/ard.2010.138594
doi: 10.1136/ard.2010.138594
pubmed: 21068095
Dinno A (2015) Nonparametric Pairwise Multiple Comparisons in Independent Groups using Dunn’s Test. Stata J Promot Commun Stat Stata 15:292–300. https://doi.org/10.1177/1536867X1501500117
doi: 10.1177/1536867X1501500117
Makles A (2012) Stata tip 110: how to get the optimal K-means cluster solution. Stata J SAGE Publ 12:347–351. https://doi.org/10.1177/1536867X1201200213
doi: 10.1177/1536867X1201200213
Jones BL, Nagin D (2012) A stata plugin for estimating group-based trajectory models. Carnegie Mellon Univ. https://doi.org/10.1184/R1/6470963.V1
doi: 10.1184/R1/6470963.V1
Sieper J, Poddubnyy D, Miossec P (2019) The IL-23–IL-17 pathway as a therapeutic target in axial spondyloarthritis. Nat Rev Rheumatol 15:747–757. https://doi.org/10.1038/s41584-019-0294-7
doi: 10.1038/s41584-019-0294-7
pubmed: 31551538
Lewis MJ, Barnes MR, Blighe K, Goldmann K, Rana S, Hackney JA et al (2019) Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes. Cell Rep 28:2455-2470.e5. https://doi.org/10.1016/j.celrep.2019.07.091
doi: 10.1016/j.celrep.2019.07.091
pubmed: 31461658
pmcid: 6718830
Sieper J, Poddubnyy D (2017) Axial spondyloarthritis. Lancet 390:73–84. https://doi.org/10.1016/S0140-6736(16)31591-4
doi: 10.1016/S0140-6736(16)31591-4
pubmed: 28110981
Goetz I, Carter GC, Lucero M, Zarotsky V, Alatorre CI, Cantrell RA et al (2011) Review of treatment response in rheumatoid arthritis: assessment of heterogeneity. Curr Med Res Opin 27:697–711. https://doi.org/10.1185/03007995.2010.549805
doi: 10.1185/03007995.2010.549805
pubmed: 21271796
Kearsley-Fleet L, Davies R, De Cock D, Watson KD, Lunt M, Buch MH et al (2018) Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 77:1405–1412. https://doi.org/10.1136/annrheumdis-2018-213378
doi: 10.1136/annrheumdis-2018-213378
pubmed: 29980575
Baganz L, Richter A, Albrecht K, Schneider M, Burmester G-R, Zink A et al (2019) Are prognostic factors adequately selected to guide treatment decisions in patients with rheumatoid arthritis? a collaborative analysis from three observational cohorts. Semin Arthritis Rheum 48:976–982. https://doi.org/10.1016/j.semarthrit.2018.09.003
doi: 10.1016/j.semarthrit.2018.09.003
pubmed: 30316460
Siemons L, ten Klooster PM, Vonkeman HE, Glas CAW, van de Laar MAFJ (2014) Distinct trajectories of disease activity over the first year in early rheumatoid arthritis patients following a treat-to-target strategy: disease activity trajectories in early RA patients. Arthritis Care Res 66:625–630. https://doi.org/10.1002/acr.22175
doi: 10.1002/acr.22175
Rivellese F, Surace AEA, Goldmann K, Sciacca E, Çubuk C, Giorli G et al (2022) Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nat Med 28:1256–1268. https://doi.org/10.1038/s41591-022-01789-0
doi: 10.1038/s41591-022-01789-0
pubmed: 35589854
pmcid: 9205785
Genitsaridi I, Flouri I, Plexousakis D, Marias K, Boki K, Skopouli F et al (2020) Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group. Arthritis Res Ther 22:226. https://doi.org/10.1186/s13075-020-02313-w
doi: 10.1186/s13075-020-02313-w
pubmed: 32993800
pmcid: 7523072
Glintborg B, Lindstrom U, Aaltonen K, Kristianslund EK, Gudbjornsson B, Chatzidionysiou K et al (2018) Biological treatment in ankylosing spondylitis in the Nordic countries during 2010–2016: a collaboration between five biological registries. Scand J Rheumatol. https://doi.org/10.1080/03009742.2018.1444199
doi: 10.1080/03009742.2018.1444199
pubmed: 30444168
Ørnbjerg LM, Linde L, Georgiadis S, Rasmussen SH, Lindström U, Askling J et al (2022) Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: data from the EuroSpA collaboration. Sem Arthritis Rheum 56:152081. https://doi.org/10.1016/j.semarthrit.2022.152081
doi: 10.1016/j.semarthrit.2022.152081
Fernández-Carballido C, Sanchez-Piedra C, Valls R, Garg K, Sánchez-Alonso F, Artigas L et al (2023) Female sex, age, and unfavorable response to tumor necrosis factor inhibitors in patients with axial spondyloarthritis: results of statistical and artificial intelligence-based data analyses of a National Multicenter Prospective Registry. Arthritis Care Res 75:115–124. https://doi.org/10.1002/acr.25048
doi: 10.1002/acr.25048
Mésidor M, Rousseau M-C, O’Loughlin J, Sylvestre M-P (2022) Does group-based trajectory modeling estimate spurious trajectories? BMC Med Res Methodol 22:194. https://doi.org/10.1186/s12874-022-01622-9
doi: 10.1186/s12874-022-01622-9
pubmed: 35836129
pmcid: 9281109
Iannone F, Semeraro A, Carlino G, Santo L, Bucci R, Quarta L et al (2019) Effectiveness of Certolizumab-Pegol in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis based on the BIOPURE registry: can early response predict late outcomes? Clin Drug Investig 39:565–575. https://doi.org/10.1007/s40261-019-00782-9
doi: 10.1007/s40261-019-00782-9
pubmed: 30941736
Iannone F, Santo L, Anelli MG, Bucci R, Semeraro A, Quarta L et al (2017) Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum 47:108–114. https://doi.org/10.1016/j.semarthrit.2017.01.008
doi: 10.1016/j.semarthrit.2017.01.008
pubmed: 28216195
Sepriano A, Ramiro S, van der Heijde D, Ávila-Ribeiro P, Fonseca R, Borges J et al (2016) Effect of comedication with conventional synthetic disease-modifying antirheumatic drugs on retention of tumor necrosis factor inhibitors in patients with spondyloarthritis: a prospective cohort study: effects of csDMARDS on tnfi retention In SpA. Arthritis & Rheumatology 68:2671–2679. https://doi.org/10.1002/art.39772
doi: 10.1002/art.39772
Choquette D, Bessette L, Alemao E, Haraoui B, Postema R, Raynauld J-P et al (2019) Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry. Arthritis Res Ther 21:138. https://doi.org/10.1186/s13075-019-1917-8
doi: 10.1186/s13075-019-1917-8
pubmed: 31171024
pmcid: 6555030
Leon L, Rodriguez-Rodriguez L, Rosales Z, Gomez A, Lamas J, Pato E et al (2016) Long-term drug survival of biological agents in patients with rheumatoid arthritis in clinical practice. Scand J Rheumatol 45:456–460. https://doi.org/10.3109/03009742.2016.1141979
doi: 10.3109/03009742.2016.1141979
pubmed: 27115843
Clark TG, Bradburn MJ, Love SB, Altman DG (2003) Survival Analysis Part I: Basic concepts and first analyses. Br J Cancer 89:232–238. https://doi.org/10.1038/sj.bjc.6601118
doi: 10.1038/sj.bjc.6601118
pubmed: 12865907
pmcid: 2394262